1. bookVolume 25 (2017): Issue 2 (April 2017)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors

Published Online: 28 Apr 2017
Page range: 135 - 143
Received: 07 Sep 2016
Accepted: 27 Feb 2017
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

The development of FVIII/FIX inhibitor alloantibodies represents a severe complication requiring specific laboratory evaluation for establishing a life-saving therapy regimen. Our preliminary study aimed at elaborating a laboratory strategy for monitoring the effectiveness of Activated Prothrombin Complex Concentrate (APCC) and recombinant activated factor VII (rFVIIa) in haemophiliacs with inhibitors, by checking the reliability and clinical value of three complementary assays: clotting-time based coagulometry, thrombelastography (TEG) and thrombin generation assay (TGA). The investigations were performed on 7 patients with severe haemophilia A with high titer inhibitors treated for 12 episodes of severe bleedings, 5 of them for surgical interventions. After the administration of bypassing agents (BPAs) the clotting-time based assay brought changes only on prothrombin (p<0.01), potentially signaling a thrombotic risk, without any impact on the global hemostasis. TEG displayed prompt significant improvement only after rFVIIa (90μg/kg). TGA revealed significantly improved values for peak and velocity index, time to peak and start tail after both BPAs. Despite some disparities between biological hemostatic phenotype and clinical response to therapy, we concluded that TEG and TGA are the only current exploratory assays, expressing the quality of haemostatic control, representing a real support for a personalized, adapted therapy in hemophilia with inhibitors.

Keywords

1. Tripodi A. The Long-Awaited Whole-Blood Thrombin Generation Test. Clin Chem. 2012;58(8):1173-5. DOI: 10.1373/clinchem.2012.18926610.1373/clinchem.2012.18926622685127Search in Google Scholar

2. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249-53. DOI: 10.1159/00007357510.1159/00007357513679651Search in Google Scholar

3. Marcus D Lance. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Lance Thrombosis J. 2015;13:1. DOI: 10.1186/1477-9560-13-110.1186/1477-9560-13-1441720425937820Search in Google Scholar

4. Kern A, Varnai K, Vasarhelyi B. Thrombin generation assays and their clinical application. Orv Hetil. 2014; 155 (22):851-7. DOI: 10.1556/OH.2014.2989910.1556/OH.2014.2989924860049Search in Google Scholar

5. Young G, Sorensen B, Dargaud Y, Negrier C, Brummel- Ziedins K, Nigel S, et al. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013; 121 (11):1944-50. DOI: 10.1182/ blood-2012-08-37893510.1182/blood-2012-08-378935364505423319573Search in Google Scholar

6. Mancuso ME, Fasulo MR. Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors. Semin Thromb Haemost. 2016;42:30-5.Search in Google Scholar

7. Mancuso ME, Chantaragkul V, Clerici M. Low thrombin generation during major orthopedic surgery fails to predict bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia. 2016;22(4):292-30. DOI: 10.1111/hae.1293910.1111/hae.1293927197961Search in Google Scholar

8. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb. 2003;33 (1):16-22. DOI: 10.1159/00007163710.1159/00007163712853708Search in Google Scholar

9. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia.2005;11(5):552-8. DOI: 10.1111/j.1365-2516.2005.01141.x10.1111/j.1365-2516.2005.01141.x16128902Search in Google Scholar

10. 1Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010; 116 (25):5734-7. DOI: 10.1182/blood-2010-06-29190610.1182/blood-2010-06-29190620810929Search in Google Scholar

11. Mancuso ME, Chantarangkul V, Clerici M. Thrombin generation assay in hemophilic patients with or without inhibitors undergoing orthopedic surgery. Haemophilia. 2014; 20 (3):10.Search in Google Scholar

12. Instrumentation laboratory ACL ELITE* / ELITE PRO System. Reagents, controls and calibrators package’s inserts. PN 722277 Rev. BB (November 2010) Beckman Coulter, Inc.Search in Google Scholar

13. Shima M, Matsumoto T, Ogiwara K New assays for monitoring haemophilia treatment. Haemophilia. 2008;3:83-92. DOI: 10.1111/j.1365-2516.2008.01737.x10.1111/j.1365-2516.2008.01737.x18510527Search in Google Scholar

14. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Coenraad Hemker H, Lindhout T, et al. Whole- Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay. Clin Chem. 2012; 58 (8):1252-9. DOI: 10.1373/ clinchem.2012.18407710.1373/clinchem.2012.18407722665918Search in Google Scholar

15. Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016; 128 (5): 630-637. DOI: 10.1182/blood-2016-01-68743410.1182/blood-2016-01-687434497419827330001Search in Google Scholar

16. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia. 2005; 11 (1):1-6. DOI: 10.1111/j.1365-2516.2005.01156.x10.1111/j.1365-2516.2005.01156.x16219042Search in Google Scholar

17. Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12:4-13. DOI: 10.1111/j.1365-2516.2006.01379.x10.1111/j.1365-2516.2006.01379.xSearch in Google Scholar

18. Dargaud Y, Prevost C, Lienhart A, Bordet JC, Negrier C. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. Haemophilia. 2011;17:957-61. DOI: 10.1111/j.1365-2516.2011.02526.x10.1111/j.1365-2516.2011.02526.x21453422Search in Google Scholar

19. Vila V, Aznar JA, Moret A, Marco A, Navarro S, Vila C, et al. Assessement of the thrombin generation assay in haemophilia: comparative study between fresh and frozen platelet-rich plasma. Haemophilia. 2013;19:318-21. DOI: 10.1111/hae.1204410.1111/hae.1204423174035Search in Google Scholar

20. Perrin J, Depasse P, Lecompte T. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalization with an external reference plasma. Thromb Res. 2016;135(1):125-130. 10.1016/j.thromres.2014.12.01525563679Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo